<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614366</url>
  </required_header>
  <id_info>
    <org_study_id>TSHDM1101</org_study_id>
    <secondary_id>DMTA07</secondary_id>
    <nct_id>NCT01614366</nct_id>
  </id_info>
  <brief_title>DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension</brief_title>
  <official_title>A Phase II Study to Explore the Effect of Different Dose of DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TSH Biopharm Corporation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TSH Biopharm Corporation Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the different dose of DMTA07 (DM) combine with
      amlodipine in the treatment of mild to moderate essential hypertension, and to define the
      optimized dose of DM in the combination therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the different dose of DM combine with amlodipine in the treatment of mild to
      moderate essential hypertension, and to define the optimized dose of DM in the combination
      therapy.

      The purpose of this study is to compare the antihypertensive efficacy and tolerability of
      different dose of DM combines with amlodipine treatment, further to explore the optimized
      combination dose of DM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>*SBP reduction=SBP each visit- SBPvisit2</measure>
    <time_frame>14 weeks</time_frame>
    <description>The primary objective of this study is to compare the sitting systolic blood pressure (mmHg) reduction* between four dose regimens, the baseline is defined as the actual SBP value after 2 weeks of amlodipine run-in period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives of the study include: Efficacy/Safety</measure>
    <time_frame>14 weeks</time_frame>
    <description>Efficacy:
To compare the sitting diastolic blood pressure (mmHg) reduction* between four dose regimens, the baseline is defined as the actual DBP value after 2 weeks of amlodipine run-in period To evaluate the percentage of SBP reduction in four treatment regimens To evaluate the changes of blood pressure (mmHg) in different clusters; such as diabetes etc.
Safety:
To evaluate the pulse rate changes To evaluate incidences of adverse events To evaluate the change of laboratory test results from baseline</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>AM 5 + DM 0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine 5 mg + DMTA07 0mg, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AM 5 + DM 2.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 5 mg + DMTA07 2.5mg, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AM 5 + DM 7.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 5 mg + DMTA07 7.5mg, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AM 5 + DM 30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 5 mg + DMTA07 30mg, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM 5 + DM 0</intervention_name>
    <description>Amlodipine 5 mg + DMTA07 0mg, once daily</description>
    <arm_group_label>AM 5 + DM 0</arm_group_label>
    <arm_group_label>AM 5 + DM 2.5</arm_group_label>
    <arm_group_label>AM 5 + DM 7.5</arm_group_label>
    <arm_group_label>AM 5 + DM 30</arm_group_label>
    <other_name>Amlodipine (AM)</other_name>
    <other_name>DMTA07 (DM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM 5 + DM 2.5</intervention_name>
    <description>Amlodipine 5 mg + DMTA07 2.5mg, once daily</description>
    <arm_group_label>AM 5 + DM 2.5</arm_group_label>
    <arm_group_label>AM 5 + DM 7.5</arm_group_label>
    <arm_group_label>AM 5 + DM 30</arm_group_label>
    <other_name>Amlodipine (AM)</other_name>
    <other_name>DMTA07 (DM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM 5 + DM 7.5</intervention_name>
    <description>Amlodipine 5 mg + DMTA07 7.5mg, once daily</description>
    <arm_group_label>AM 5 + DM 7.5</arm_group_label>
    <arm_group_label>AM 5 + DM 30</arm_group_label>
    <other_name>Amlodipine (AM)</other_name>
    <other_name>DMTA07 (DM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM 5 + DM 30</intervention_name>
    <description>Amlodipine 5 mg + DMTA07 30mg, once daily</description>
    <arm_group_label>AM 5 + DM 30</arm_group_label>
    <other_name>Amlodipine (AM)</other_name>
    <other_name>DMTA07 (DM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient aged between 50 to 75 years old (both included);

          2. Patient with mild to moderate essential hypertension at enrollment, which defined as
             the following:

             Patient must have mean sitting SBP ≥140 and &lt;180 mmHg or mean sitting DBP ≥90 and &lt;110
             mmHg at enrollment;

          3. Patient with normal serum potassium;

          4. Patient or his/her legally acceptance representative has signed the written informed
             consent form.

        Exclusion Criteria:

          1. Patient with severe hypertension (mean sitting DBP ≥ 110 mmHg or mean sitting SBP ≥
             180 mmHg);

          2. Patient with secondary hypertension, such as coarctation of aorta, hyperaldosteronism,
             unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma,
             polycystic kidney disease, etc;

          3. Patient is under treatment with beta-blocker prior to enrollment;

          4. A definite diagnosis or unstable of cardiovascular disease, including angina pectoris,
             myocardial infarction, coronary artery bypass graft, percutaneous transluminal
             coronary angioplasty, transient ischemic attack, stroke, arrhythmia and heart failure
             within 3 months before signing the written informed consent form;

          5. Patient with concomitant endocrine diseases or type 1 Diabetes Mellitus;

          6. Patient with type 2 Diabetes Mellitus with poor glucose control (glycosylated
             hemoglobin &gt; 9% or fasting blood sugar &gt; 250 mg/dL at enrollment) or under insulin
             treatment;

          7. Patient with clinically unstable disease such as known collagen or auto-immune disease
             or other malignant disease requiring current medication;

          8. Patient with bilateral renal artery stenosis, solitary kidney or post renal
             transplant;

          9. Patient with clinically relevant hematological disease;

         10. Hepatic or renal dysfunction as defined by the following parameters:

               -  ALT or AST &gt; 2 times upper limit of normal,

               -  Total bilirubin &gt; 2 times upper limit of normal,

               -  Serum creatinine &gt;2.0 mg/dl;

         11. Female patient who is pregnant or lactating;

         12. Patient with substance abuse (including alcohol) history for the past two years;

         13. Known or suspected contraindications, including allergy to DMTA07 or calcium channel
             blockers;

         14. Patient received other investigational drug or device within 30 days before signing
             the written informed consent form;

         15. Patient with any other serious disease considered by the investigator(s) not in the
             condition to enter the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaw-Wen Chen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>VGHTP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>E-DA Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>824</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheng Hsin General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan County</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>November 11, 2015</last_update_submitted>
  <last_update_submitted_qc>November 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amlodipine</keyword>
  <keyword>DMTA07</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

